Pham Quang X 4

What Happened Quang Pham, a 10% owner of Cadrenal Therapeutics (CVKD), reported three open‑market sales (code S) executed in May 2026 totaling 12,763 shares for aggregate proceeds of approximately $69,451. The sales were: 6,476 shares on 2026-05-11 at an average $5.76 ($37,302); 3,298 shares on 2026-05-12 at an average $5.28 ($17,413); and 2,989 shares on 2026-05-28 at an average $4.93 ($14,736). The May 11 sale was executed under a Rule 10b5-1 trading plan adopted September 25, 2025.

Key Details

• Transaction dates & reported averages:
  • 2026-05-11: 6,476 shares @ $5.76 — $37,302 (footnote: price is a weighted average; individual trades ranged $5.47–$6.12).
  • 2026-05-12: 3,298 shares @ $5.28 — $17,413 (weighted average; range $5.07–$5.535).
  • 2026-05-28: 2,989 shares @ $4.93 — $14,736 (weighted average; range $4.81–$5.07).
• Total sold: 12,763 shares for ~$69,451.
• Ownership after transaction: the filing corrects a prior Form 4 understatement (see footnotes F3 and F6). The precise "owned after" figure is provided in the full Form 4.
• Notable footnotes: F1 confirms the May 11 sales were under a pre-established Rule 10b5-1 plan; F2/F4/F5 explain reported prices are weighted averages with ranges and that transaction-level detail is available on request; F7 notes Mr. Pham holds certain shares as Trustee of The PVBQ Living Trust and has sole voting/dispositive power for that trust.
• Timeliness: The filing on 2026-05-29 follows the transactions (earliest 2026-05-11) and the prior Form 4 filed 2026-05-26 was amended here — the record indicates late reporting relative to the typical 2-business-day Form 4 deadline.

Context These were disposals by a 10% owner and include trades executed under a pre‑arranged 10b5‑1 plan, which typically reflect scheduled sales rather than contemporaneous insider reactions. Sales are common and do not, by themselves, indicate company prospects; purchases generally carry more direct bullish signal for retail investors. For precise post‑trade holdings and the detailed breakdown of prices for each individual trade, consult the full Form 4 filing (Accession 0001213900-26-062862).